Novo Nordisk has selected two providers — Form Health and 9amHealth — to offer obesity care for patients who access Wegovy (semaglutide) and Saxenda (liraglutide) through its direct-to-patient NovoCare platform.

“Obesity and related cardiometabolic conditions require more than a prescription; they demand comprehensive, reliable care,” Florencia Halperin, M.D., MMSc, chief medical officer of Form Health, said in a news release .

Form Health’s care team includes a certified physician, advanced practice providers and registered dietitians with specialized training in obesity treatment. They can develop individualized treatment plans that address behavioral health, nutrition and physical activity, as well as prescriptions for weight loss medications.

“We’re in the midst of a once-in-a-lif

See Full Page